

Concise Review: Isolation and Characterization of Cells from Human Term Placenta: Outcome of the First International Workshop on Placenta Derived Stem Cells

ORNELLA PAROLINI,^a FRANCESCO ALVIANO,^b GIAN PAOLO BAGNARA,^b GROZDANA BILIC,^c HANS-JÖRG BÜHRING,^d MARCO EVANGELISTA,^a SIMONE HENNERBICHLER,^e BING LIU,^f MARTA MAGATTI,^a NING MAO,^f TOSHIO MIKI,^g FABIO MARONGIU,^g HIDEAKI NAKAJIMA,^h TOSHIO NIKAIDO,ⁱ C. BETTINA PORTMANN-LANZ,^j VENKATACHALAM SANKAR,^k MADDALENA SONCINI,^a GUIDO STADLER,^e DANIEL SURBEK,^j TSUNEO A. TAKAHASHI,^h HEINZ REDL,^e NORIO SAKURAGAWA,^l SUSANNE WOLBANK,^e STEFFEN ZEISBERGER,^c ANDREAS ZISCH,^c STEPHEN C. STROM^g

^aCentro di Ricerca E. Menni, Fondazione Poliambulanza, Istituto Ospedaliero, Brescia, Italy; ^bDepartment of Histology, Embryology and Applied Biology, University of Bologna, Bologna, Italy; ^cDepartment of Obstetrics, University Hospital Zurich, Zurich, Switzerland; ^dDepartment of Internal Medicine II, University Clinic of Tübingen, Tübingen, Germany; ^eRed Cross Blood Transfusion Service of Upper Austria/Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Linz-Vienna, Austria; ^fDepartment of Cell Biology, Institute of Basic Medical Sciences, Beijing, China; ^gDepartment of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA; ^hInstitute of Medical Science, University of Tokyo, Tokyo, Japan; ⁱDepartment of Regenerative Medicine, University of Toyama Faculty of Medicine, Toyama, Japan; ^jDepartment of Obstetrics and Gynaecology, University of Berne, Berne, Switzerland; ^kDepartment of Anatomy, University of Madras, Chennai, India; ^lDepartment of Regenerative Medicine, Kitasato University, Kanagawa, Japan

Key Words. Human placenta • Fetal membranes • Amnion • Chorion • Mesenchymal stromal cells • Fetal tolerance

ABSTRACT

Placental tissue draws great interest as a source of cells for regenerative medicine because of the phenotypic plasticity of many of the cell types isolated from this tissue. Furthermore, placenta, which is involved in maintaining fetal tolerance, contains cells that display immunomodulatory properties. These two features could prove useful for future cell therapy-based clinical applications. Placental tissue is readily available and easily procured without invasive procedures, and its use does not elicit ethical debate. Numerous reports describing stem cells from different parts of the placenta, using nearly as numerous isolation and characterization procedures, have been published. Considering the complexity of the placenta, an urgent need exists to define, as clearly

as possible, the region of origin and methods of isolation of cells derived from this tissue. On March 23–24, 2007, the first international Workshop on Placenta Derived Stem Cells was held in Brescia, Italy. Most of the research published in this area focuses on mesenchymal stromal cells isolated from various parts of the placenta or epithelial cells isolated from amniotic membrane. The aim of this review is to summarize and provide the state of the art of research in this field, addressing aspects such as cell isolation protocols and characteristics of these cells, as well as providing preliminary indications of the possibilities for use of these cells in future clinical applications. *STEM CELLS* 2008;26:300–311

Disclosure of potential conflicts of interest is found at the end of this article.

INTRODUCTION

Human placenta, besides playing a fundamental and essential role in fetal development, nutrition, and tolerance, may also represent a reserve of progenitor/stem cells. Considering the complexity of the structure of the placenta, we have focused our attention on cells isolated from the amniotic and chorionic fetal membranes and reached a consensus on the minimal criteria for definition of mesenchymal cells derived from both of these membranes. Cord blood and amniotic fluid-derived cells are not included in this discussion.

From the data presented by the participants, the following points were evident.

- Cells isolated from placental tissue should be verified to be of fetal origin (using methods sensitive enough to detect maternal contamination of 1% or less).
- Four regions of fetal placenta can be distinguished: amniotic epithelial, amniotic mesenchymal, chorionic mesenchymal, and chorionic trophoblastic. From these regions, the following cell populations are isolated: human amniotic epithelial cells (hAEC), human amniotic mesenchymal stromal cells

Correspondence: Ornella Parolini, Ph.D., Centro di Ricerca E. Menni, Fondazione Poliambulanza, Istituto Ospedaliero, Via Bissolati 57, 25124 Brescia, Italy. Telephone: 39-030-2455-754; Fax: 39-030-2455-704; e-mail: ornella.parolini@tin.it Received July 24, 2007; accepted for publication October 18, 2007; first published online in *STEM CELLS EXPRESS* November 1, 2007; available online without subscription through the open access option. ©AlphaMed Press 1066-5099/2008/\$30.00/0 doi: 10.1634/stemcells.2007-0594

Table 1. Specific surface antigen expression at passages 2–4 for amniotic mesenchymal stromal cells and human chorionic mesenchymal stromal cells

Positive ($\geq 95\%$)	Negative ($\leq 2\%$)
CD90	CD45
CD73	CD34
CD105	CD14
	HLA-DR

(hAMSC), human chorionic mesenchymal stromal cells (hCMSC), and human chorionic trophoblastic cells (hCTC).

- Cells from each layer demonstrate variable plasticity. Because of their plasticity, the term stem cell has been used in the literature to describe a number of cells isolated from placenta. Self renewal and “hierarchy,” which are normally considered a hallmark of stem cells, have not been clearly demonstrated in the different placenta derived cell types, and therefore the term “stem cell” at this time is not always appropriate. However, it may be interesting to mention that recent reports propose an alternative stem cell concept whereby plasticity is essential to define stemness, and self renewal and hierarchy are optional characteristics [1, 2].
- According to criteria recently proposed by Dominici et al. for bone marrow-derived mesenchymal stromal cells [3], mesenchymal cells isolated from fetal membranes should be termed mesenchymal stromal cells (hAMSC and hCMSC).

Minimal criteria for defining hAMSC and hCMSC are as follows:

- Adherence to plastic;
- Formation of fibroblast colony-forming units;
- A specific pattern of surface antigen expression (Table 1);
- Differentiation potential toward one or more lineages, including osteogenic, adipogenic, chondrogenic, and vascular/endothelial; and
- Fetal origin.

The participants of the workshop concluded that placenta is an important source of stem/progenitor cells, and additional useful cell types in this tissue may yet be defined. Here, we briefly describe the structure of this organ and discuss isolation, characterization, and differentiation protocols for hAEC, hAMSC, and hCMSC, as well as the immunomodulatory properties, in vitro and in vivo preclinical studies, and cell banking strategies for these cell populations. We do not include hCTC in our discussion as very little definitive information has been published on these cells to date.

THE PLACENTA

Placental Compartments

The fetal adnexa is composed of the placenta, fetal membranes, and umbilical cord. The term placenta is discoid in shape with a diameter of 15–20 cm and a thickness of 2–3 cm. From the margins of the chorionic disc extend the fetal membranes, amnion and chorion, which enclose the fetus in the amniotic cavity, and the endometrial decidua. The chorionic plate (Fig. 1) is a multilayered structure that faces the amniotic cavity. It consists of two different structures: the amniotic membrane (composed of epithelium, compact layer, amniotic mesoderm, and spongy layer) and the chorion (composed of mesenchyme and a region of extravillous proliferating trophoblast cells interspersed in varying amounts of Langhans fibrinoid, either covered or not by syncytiotrophoblast). Villi originate from the chorionic plate and anchor the placenta through the trophoblast of the basal plate and maternal endometrium. From the maternal side, protrusions of the basal plate within the chorionic villi produce the placental septa, which divide the parenchyma into irregular cotyledons (Fig. 1).

Some villi anchor the placenta to the basal plate, whereas others terminate freely in the intervillous space. Chorionic villi present with different functions and structure. In the term placenta, the stem villi show an inner core of fetal vessels with a distinct muscular wall and connective tissue consisting of fibroblasts, myofibroblasts, and dispersed tissue macrophages (Hofbauer cells). Mature intermediate villi and term villi are composed of capillary vessels and thin mesenchyme. A basement membrane separates the stromal core from an uninterrupted multinucleated layer, called syncytiotrophoblast. Between the syncytiotrophoblast and its basement membrane are single or aggregated Langhans cytotrophoblastic cells, commonly called cytotrophoblast cells.

Fetal membranes continue from the edge of the placenta and enclose the amniotic fluid and the fetus. The amnion is a thin, avascular membrane composed of an epithelial layer and an outer layer of connective tissue, and is contiguous, over the umbilical cord, with the fetal skin. The amniotic epithelium (AE) is an uninterrupted, single layer of flat, cuboidal and columnar epithelial cells in contact with amniotic fluid. It is attached to a distinct basal lamina that is, in turn, connected to the amniotic mesoderm (AM) (Fig. 2). In the amniotic mesoderm closest to the epithelium, an acellular compact layer is distinguishable, composed of collagens I and III and fibronectin. Deeper in the AM, a network of dispersed fibroblast-like mes-




Figure 1. Schematic section of the human term placenta. During placenta formation, from the maternal side, protrusions of the basal plate within the chorionic villi produce the placental septa, which divide the parenchyma into irregular cotyledons. Each cotyledon contains several villi, which originate from the chorionic plate. Fetal blood vessels are located within the branches of the villi.




Figure 2. Cross-sectional representation of human fetal membranes (amnion and chorion). The amnion is composed of an epithelial layer of cuboidal and columnar cells, which lie on top of a mesodermal layer consisting of an upper acellular compact layer and a deeper layer containing dispersed fibroblasts. The chorionic membrane consists of a mesodermal layer and a layer of extravillous trophoblast cells. Abbreviations: AE; amniotic epithelium; AM, amniotic mesoderm; CM, chorionic mesoderm; CT, chorionic trophoblast.

enchymal cells and rare macrophages are observed. Very recently, it has been reported that the mesenchymal layer of amnion indeed contains two subfractions, one having a mesenchymal phenotype, which is referred to throughout this review as amniotic mesenchymal stromal cells, and the second containing monocyte-like cells [4].

A spongy layer of loosely arranged collagen fibers separates the amniotic and chorionic mesoderm (Fig. 2). The chorionic membrane (chorion leave) consists of mesodermal and trophoblastic regions (Fig. 2). Chorionic and amniotic mesoderm are similar in composition. A large and incomplete basal lamina separates the chorionic mesoderm from the extravillous trophoblast cells. The latter, similar to trophoblast cells present in the basal plate, are dispersed within the fibrinoid layer and express immunohistochemical markers of proliferation. The Langhans fibrinoid layer usually increases during pregnancy and is composed of two different types: a matrix type on the inner side (more compact) and a fibrin type on the outer side (more reticulate). At the edge of the placenta and in the basal plate, the trophoblast interdigitates extensively with the deciduas [5, 6].

Embryological Development

In humans, by days 6–7 after fertilization (during the implantation window), the blastocyst implants and placenta development begins. At this stage, the blastocyst is flattened and composed of an outer wall (trophoblast) that surrounds the blastocystic cavity. A small group of larger cells, the inner cell mass, is apposed to the inner surface of the trophoblastic vesicle. The embryo, umbilical cord, and amniotic epithelium are derived from the inner cell mass. As the blastocyst adheres to the endometrium, invading trophoblasts erode the decidua, facilitating implantation of the blastocyst. By 8–9 days after fertilization, trophoblastic cells at the implanting pole of the blastocyst proliferate robustly, forming a bilayered trophoblast. The outer of the two layers becomes the syncytiotrophoblast by fusion of neighboring trophoblast cells, whereas the inner cells (cytotrophoblast) remain temporally unfused.

The proliferating cytotrophoblasts and the syncytiotrophoblasts give rise to a system of trabeculae intermingled with

hematic lacunae. From these trabeculae are generated the primordial villi that are distributed over the entire periphery of the chorionic membrane. Villi in contact with the decidua basalis proliferate to form the leafy chorion or chorion frondosum, whereas villi in contact with the decidua capsularis degenerate into the chorion leave.

At day 8–9 after fertilization, the inner cell mass differentiates into two layers: the epiblast and the hypoblast. Subsequently, from the epiblast, small cells that later constitute the amniotic epithelium appear between the trophoblast and the embryonic disc and enclose a space that will become the amniotic cavity. On the opposite side, between the hypoblast and cytotrophoblast, the exocoelomic membrane and its cavity modify to form the yolk sac. The extraembryonic mesoderm arranges into a connective tissue that surrounds the yolk sac and amniotic cavity, giving rise to amniotic and chorionic mesoderm. Gastrulation, the process through which the bilaminar disc differentiates into the three germ layers (ectoderm, mesoderm, and endoderm) and develops a defined form, with a midline and cranio-caudal, right-left, and dorsal-ventral body axes, occurs during the 3rd week after fertilization [6, 7].

FETAL PLACENTA TISSUE CELL POPULATIONS

Human Amniotic Epithelial Cells

Recent reports indicate that hAEC express stem cell markers and have the ability to differentiate toward all three germ layers. These properties, the ease of isolation of the cells, and the availability of placenta as a discard tissue, make the amnion a potentially useful and noncontroversial source of cells for transplantation and regenerative medicine. For isolation of epithelial cells, the amniotic membrane is stripped from the underlying chorion and digested with trypsin or other digestive enzymes (Table 2) [8–11]. Epithelial cells are specifically released by brief trypsin digests of 20–40 minutes each. A detailed protocol is available providing a step-by-step isolation procedure along with photos of the process [12]. Isolated cells readily attach to plastic or basement membrane-coated culture dishes. Culture is commonly established in a simple medium such as Dulbecco's modified Eagle's medium supplemented with 5%–10% serum and epidermal growth factor (EGF) (Table 2), where the cells proliferate robustly and display typical cuboidal epithelial morphology [10, 11, 13]. Normally, 2–6 passages are possible before proliferation ceases. Cells do not proliferate well at low densities. Amniotic membrane contains epithelial cells with different surface markers, suggesting some heterogeneity of phenotype. Immediately after isolation, hAEC appear to express very low levels of human leukocyte antigen (HLA)-A,B,C [10]; however, by passage 2, significant levels are observed (Table 2). Additional cell surface antigens on hAEC include ATP-binding cassette transporter G2 (ABCG2/BCRP), CD9, CD24, E-cadherin, integrins $\alpha 6$ and $\beta 1$, c-met (hepatocyte growth factor receptor), stage-specific embryonic antigens (SSEAs) 3 and 4, and tumor rejection antigens 1-60 and 1-81 [11, 14]. Surface markers thought to be absent on hAEC include SSEA-1, CD34, and CD133, whereas other markers, such as CD117 (c-kit) and CCR4 (CC chemokine receptor), are either negative or may be expressed on some cells at very low levels. Although initial cell isolates express very low levels of CD90 (Thy-1), the expression of this antigen increases rapidly in culture [11, 14]. Additional surface markers are presented in Table 2.

In addition to surface markers, hAEC express molecular markers of pluripotent stem cells, including octamer-binding protein 4 (OCT-4), SRY-related HMG-box gene 2 (SOX-2), and

Table 2. Human amniotic epithelial cells: isolation protocols, phenotype, and in vitro differentiation

Procedure	Procedure description	References
Isolation protocols	Mechanical peeling of amnion membrane from the underlying chorion followed by digestion with the following: dispase II (2.4 U/ml) for 1 hour or trypsin-EDTA (different concentrations and incubation times). Centrifugation (200g for 10 minutes) of solution containing released cells, discarding the remaining membrane	[9, 11, 12, 22, 24, 28, 29, 31, 133]
Phenotype at passages 2–4	Mesenchymal and hematopoietic markers: CD105+, CD90+, CD73+, CD44+, CD29+, HLA-A,B,C+, CD13+, CD10+, CD166+, CD49d-, CD49e+, CD117 (+/- very weak signal), CD14-, CD34-, CD45-, HLA-DR- Embryonic cell markers: SSEA-3+, SSEA-4+, TRA 1-60+, TRA 1-81+, SSEA-1- Others: CD324 (E-cadherin)+, POU5F1+, SOX2+, CFC1+, NANOG+, DPPA3+, PROM1+, PAX6+, FOXD3-, GDF3-, CD140b+, CD349-, GCTM2+	[11, 28, 29, 133] (Bühning HJ, Trembl S, Cerabona F et al., unpublished data)
Differentiation potential	Adipogenic	DMEM high glucose (or DMEM/Ham's F-12 medium), 10% FBS, 0.5 mM isobutylmethylxanthine, 1 μM dexamethasone, 10 μM insulin, 200 μM indomethacin
	Chondrogenic	DMEM high glucose, 1% FBS, 6.25 μg/ml insulin, 10 ng/ml TGF-β1, 50 ng/ml fresh ascorbic acid
	Osteogenic	DMEM high glucose (or DMEM/Ham's F-12 medium), 10% FBS, 10 μM dexamethasone, 10 nM 1-α,25-dehydroxyvitamin D3, 50 μg/ml ascorbic acid, 10 mM β-glycerophosphate
		MesenCult Human Osteogenic Stimulatory Kit (StemCell Technologies, Vancouver, BC, Canada, http://www.stemcell.com)
	Skeletal myogenic	DMEM/Ham's F-12 medium (or DMEM high glucose), 10% FBS, 5% human serum (or horse serum), 50 μM hydrocortisone (0.1 μM dexamethasone)
	Cardiomyogenic	DMEM, 10% FBS, 55 μM 2-mercaptoethanol, 1 mM sodium pyruvate, 1 mM ascorbic acid 2-phosphate
	Neurogenic	DMEM/Ham's F-12 medium, 10% FBS, 1 mM ascorbic acid
		DMEM high glucose, 10% FBS, 30 μM all-trans retinoic acid
		DMEM, 10% FBS, 55 μM 2-mercaptoethanol, 1 mM sodium pyruvate, 5 × 10 ⁻⁵ M all-trans retinoic acid, 10 ng/ml FGF-4
		DMEM/Ham's F-12 medium, 10% FCS, 5 × 10 ⁻⁵ M all-trans retinoic acid, 10 ng/ml FGF4, N-2, B-27
	Pancreatic	DMEM, 10% FBS, 55 μM 2-mercaptoethanol, 1 mM sodium pyruvate, 10 mM nicotinamide on collagen I-coated plate
		DMEM (or DMEM/Ham's F-12 medium) containing N ₂ supplement (Gibco, Grand Island, NY, http://www.invitrogen.com), 10 mM nicotinamide
	Hepatic	DMEM, 10% FBS, 55 μM 2-mercaptoethanol, 1 mM sodium pyruvate, dexamethasone 10 ⁻⁷ M, 0.1 μM insulin for 3 weeks, addition of 1 mM phenobarbital for the final 3 days, on collagen I-coated plate
		DMEM, 10% FBS, 20 ng/ml HGF, 10 ng/ml FGF-2, 10 ng/ml oncostatin M, 100 nM dexamethasone, 10 U/ml heparin sodium salt
		DMEM/Ham's F-12 medium, 10% FCS + 0.1 μM insulin, 1 × 10 ⁻⁷ M dexamethasone

Abbreviations: DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; FCS, fetal calf serum; HGF, hepatocyte growth factor; SSEA, stage-specific embryonic antigen; TGF, transforming growth factor; TRA, tumor rejection antigen.

Nanog [11]. The suggestion that hAEC may be pluripotent was supported by the report by Tamagawa et al. [15]. These investigators created a xenogeneic chimera of human amnion cells with mouse embryonic stem cells, in vitro. Chimeric aggregates were maintained, and human contribution to all three germ layers was established. Later studies indicated that differentiation of hAEC can be directed. Sakuragawa et al. identified neural and glial markers on cultured hAEC [16]. Later studies reported that cultured hAEC synthesize and release acetylcholine, catecholamines [9, 17, 18], and dopamine [19, 20]. Hepatic differentiation of hAEC was also reported. Sakuragawa et al.

reported that cultured hAEC produce albumin (Alb) and α-fetoprotein (AFP) and that Alb- and AFP-positive hepatocyte-like cells could be identified integrated into hepatic parenchyma following transplantation of hAEC into the livers of severe combined immunodeficiency (SCID) mice [21]. The hepatic potential of hAEC was confirmed and extended [11, 22, 23], whereby in addition to Alb and AFP production, other hepatic functions, such as glycogen storage and expression of liver-enriched transcription factors, such as hepatocyte nuclear factor (HNF) 3γ and HNF4α, CCAAT/enhancer-binding protein (CEBP α and β), and several of the drug metabolizing




Figure 3. Culture of placenta derived stem cell types (phase contrast micrograph pictures; magnification, $\times 200$). (A): Primary human amniotic epithelial cell culture. (B): Human amniotic mesenchymal stromal cells, passage 4. (C): Human chorionic mesenchymal stromal cells, passage 4.

genes (cytochrome P450) could be demonstrated. The wide range of hepatic genes and functions identified in hAEC suggests that these cells may be useful for liver-directed cell therapy.

Differentiation of hAEC to another endodermal tissue, pancreas, was also reported. Wei et al. [24] cultured hAEC for 2–4 weeks in the presence of nicotinamide to induce pancreatic differentiation. Subsequent transplantation of the insulin-expressing hAEC corrected the hyperglycemia of streptozotocin-induced diabetic mice. In the same setting, hAMSC were ineffective, suggesting that hAEC, but not hAMSC, were capable of acquiring a β -cell fate.

The studies reviewed above indicate that hAEC are unique cells with many stem cell characteristics. Cell types from all three germ layers were produced in vitro. There is currently strong in vitro and in vivo evidence of neural, pancreatic, and hepatic differentiation of hAEC.

Mesenchymal Stromal Cells from Amnion and Chorion: hAMSC and hCMSC

hAMSC and hCMSC are thought to be derived from extraembryonic mesoderm [7]. Extensive phenotypical and functional characterization is available on hAMSC [25–29], whereas there are few reports of investigations on hCMSC [28, 30, 31]. The available details are summarized in Tables 3 and 4.

hAMSC and hCMSC can be isolated from first-, second-, and third-trimester mesoderm of amnion and chorion, respectively [25–29, 31]. Here, when using the terms hAMSC and hCMSC we refer to cells from term placenta unless otherwise specified. For hAMSC, isolations are usually performed with term amnion dissected from the deflected part of the fetal membranes to minimize the presence of maternal cells. Homogenous hAMSC populations can be obtained by a two-step procedure: minced amnion tissue is treated with trypsin to remove hAEC, and the remaining mesenchymal cells are then released by digestion with collagenase [32] or collagenase and DNase [33]. The yield from term amnion is about 1 million hAMSC and 10-fold more hAEC per gram of tissue [33].

hCMSC are isolated from both first- and third-trimester chorion after mechanical and enzymatic removal of the trophoblastic layer with dispase. Chorionic mesodermal tissue is then digested with collagenase [28] or collagenase plus DNase [31]. Mesenchymal cells have also been isolated from chorionic fetal villi through explant culture, although maternal contamination is more likely [30, 31, 34].

Both hAMSC and hCMSC adhere and proliferate on tissue culture plastic and can be kept until passages 5–10. Reports suggest that hAMSC proliferation slows beyond passage 2, although both first-trimester hAMSC and hCMSC proliferate better than third-trimester cells [28]. Theoretically, term amnion may yield up to 5×10^8 hAMSC [35]; however, in practice, yields are typically 4 million hAMSC per 100 cm² of starting material, with a fourfold expansion after 1 month (two passages) (G. Bilic, S. Zeisberger, and A.H. Zisch, unpublished data).

Phase micrographs (Fig. 3) show the distinct morphology of

cultured hAMSC, hCMSC, and hAEC. Expression of CD49d ($\alpha 4$ integrin) on hAMSC distinguishes them from hAEC [29]. In culture, neither vimentin nor cytokeratin 18 expression is specific for hAMSC or hAEC, respectively. Transmission electron microscopy of hAMSC shows mesenchymal and epithelial characteristics. This hybrid phenotype is interpreted as a sign of multipotentiality and is not found in hCMSC, which are more primitive and metabolically quiescent. Specifically, compared with hAMSC, transmission electron microscopy of hCMSC show a simpler cytoplasmic organization. The most relevant features include the presence of stacks of rough endoplasmic reticulum cisternae, dispersed mitochondria and glycogen lakes, whereas features of higher specialization, such as presence of assembled contractile filaments, prominence of endocytotic traffic, and junctional communications, are lacking. Overall, the ultrastructural characteristics of hCMSC resemble those found in the hematopoietic progenitors and in the blue small round cell tumors (e.g., Ewing sarcomas), suggesting their position at the higher levels of the stem cell hierarchy [36]. The surface marker profile of cultured hAMSC, hCMSC, and mesenchymal stromal cells (MSC) from adult bone marrow are similar. All express typical mesenchymal markers (Table 1) but are negative for hematopoietic (CD34 and CD45) and monocytic markers (CD14) [26, 28, 29, 31]. Surface expression of SSEA-3 and SSEA-4 and RNA for OCT-4 has been reported [24, 29, 35, 37] (G. Bilic, S. Zeisberger, and A.H. Zisch, unpublished data). However, immunofluorescence staining of mesenchyme tissue did not detect SSEA-3 or SSEA-4 [39]. Both first- and third-trimester hAMSC and hCMSC express low levels of HLA-A,B,C but not HLA-DR [28, 29], indicating an immunoprivileged status.

Both hAMSC and hCMSC differentiate toward “classic” mesodermal lineages (osteogenic, chondrogenic, and adipogenic) [26, 28, 29, 31, 35], and differentiation of hAMSC to all three germ layers—ectoderm (neural), mesoderm (skeletal muscle, cardiomyocytic and endothelial), and endoderm (pancreatic)—was reported (Table 3). Questions remain as to the proportion of hAMSC that exhibit plasticity and the full maturation of progeny [39].

Human amniotic and chorionic cells successfully and persistently engraft in multiple organs and tissues in vivo. Human chimerism detection in brain, lung, bone marrow, thymus, spleen, kidney, and liver after either intraperitoneal or intravenous transplantation of human amnion and chorion cells into neonatal swine and rats was indeed indicative of an active migration consistent with the expression of adhesion and migration molecules (L-selectin, VLA-5, CD29, and P-selectin ligand 1), as well as cellular matrix proteinases (MMP-2 and MMP-9) [41].

IMMUNOLOGY OF THE PLACENTA

Maternal acceptance of the fetal allograft is not completely understood. The paradox of maternal tolerance of the fetus was first raised more than 50 years ago by Peter Medawar, who proposed that: (a) there is a physical separation between the

Table 3. Human amniotic mesenchymal stromal cells: isolation protocols, phenotype, and in vitro differentiation

Procedure	Procedure description	References
Isolation protocols	Mechanical peeling of amnion membrane from the underlying chorion followed by digestion with various concentrations of collagenase (0.75–2 mg/ml) and DNase (20–75 μ g/ml) for 30–120 minutes at 37°C	[27–29, 31–33, 37, 38]
Phenotype at passages 2–4	Mesenchymal and hematopoietic markers: CD105+, CD90+, CD73+, CD44+, CD29+, HLA-A,B,C+, CD13+, CD10+, CD49c+, CD49d+, CD49e+, CD54+, CD166+, CD271 ^{low} , CD14–, CD34–, CD45–, CD31–, HLA-DR–, CD133–, CD3– Embryonic cell marker: Oct-4+ Others: CD349+, CD140b+, CD324 (E-cadherin)–	[26, 28, 29, 31, 35] (Bühring HJ, Treml S, Cerabona F et al., unpublished data)
Differentiation potential	Adipogenic	DMEM, 10% FCS, 0.5 mM isobutylmethylxanthine, 200 μ M indomethacin, 10 ^{–6} M dexamethasone, 10 μ g/ml insulin Bullet Kit Adipogenic Differentiation Media (Cambrex, Walkersville, MD, http://www.cambrex.com)
	Chondrogenic	DMEM high glucose, 1% FBS, 6.25 μ g/ml insulin, 10 ng/ml TGF- β 1, 50 ng/ml fresh ascorbic acid DMEM, 6.25 μ g/ml insulin, 6.25 μ g/ml transferrin, 6.25 μ g/ml selenous acid, 5.33 μ g/ml linolenic acid, 1.25 mg/ml BSA, 0.35 mM proline, 1 mM sodium pyruvate, 10 ^{–7} M dexamethasone, 0.1 mM L-ascorbic acid-2-phosphate supplemented with 10 ng/ml transforming growth- β -3 DMEM, 100 nM dexamethasone, 50 μ g/ml L-ascorbic acid 2-phosphate, 1 mM sodium pyruvate, 40 μ g/ml proline, ITS (5 μ g/ml insulin, 5 μ g/ml transferrin, 5 ng/ml selenous acid), 5 ng/ml TGF- β 1
	Osteogenic	DMEM high glucose, 10% FBS, 10 mM β -glycerophosphate, 50–200 μ g/ml ascorbic acid, 10 ^{–8} M dexamethasone, 1, α 25-dihydroxyvitamin-D3 Commercial media: MesenCult Human Osteogenic Stimulatory Kit (StemCell Technologies); Bullet Kit Osteogenic Differentiation Media (Cambrex)
	Skeletal myogenic	DMEM high glucose, 10% FBS, 5% horse serum, 50 μ M hydrocortisone, 0.1 μ M dexamethasone DMEM, 5% FBS, 40 (Sigma) MCDB-201%, ITS-LA*BSA 100 \times , 10 ^{–8} M dexamethasone, 10 ^{–8} M ascorbic acid-2-phosphate, 10 ng/ml bFGF, 10 ng/ml VEGF, 10 ng/ml insulin-like growth factor-1
	Angiogenic	Matrigel adherence, 50 ng/ml VEGF, 2% FBS
	Neurogenic	DMEM high glucose, 10% FBS, 30 μ M all-trans retinoic acid DMEM, 100 μ M butylated hydroxyanisole, 10 μ M forskolin, 2% DMSO, 5 U/ml heparin, 5 nM K252a, 25 mM KCl, 2 mM valproic acid, 1 \times N2 supplement, 10 ng/ml bFGF, 10 ng/ml PDGF-BB
	Pancreatic	DMEM containing N ₂ supplement (Gibco), 10 mM nicotinamide
	Cardiomyogenic	DMEM, 10% FBS, 10 ng/ml bFGF, 50 ng/ml activin A Mixed ester of hyaluronan with butyric and retinoic acid treatment

Abbreviations: bFGF, basic fibroblast growth factor; BSA, bovine serum albumin; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; FCS, fetal calf serum; ITS-LA, insulin transferrin selenous acid-linolenic acid; MCDB, molecular cellular and developmental biology; PDGF, platelet-derived growth factor; TGF, transforming growth factor; VEGF, vascular endothelial growth factor.

mother and fetus, (b) the fetus is antigenically immature, and (c) the mother possesses an immunological inertness [42]. Since the time of Medawar, several mechanisms that contribute to tolerance induction have been proposed, although how they are regulated and driven to interact with each other remain unclear.

In particular, different explanations have been proposed regarding the regulation of maternal T-cell proliferation at the fetal maternal interface. It has been shown that some cells of the syncytiotrophoblast express the tryptophan catabolizing enzyme indoleamine 2,3-dioxygenase (IDO), resulting in the depletion of tryptophan and inhibition of T-cell proliferation, which may provide protection of the fetus from maternal T-cells [43, 44].

However, in IDO knockout mice, fetus rejection was not observed [45]. Therefore, even though IDO activity has been hypothesized as a key mechanism for protecting the allogeneic fetus, it is not the sole determinant since other mechanisms, perhaps redundant in normal mice, can compensate for the loss of IDO activity during gestation.

Furthermore, soluble HLA-G molecules produced by placenta induce apoptosis of activated CD8+ T-cells [46] and inhibit CD4+ T-cell proliferation [46]. Trophoblast cells expressing HLA-G may also inhibit natural killer cells that could induce fetal rejection [48]. In addition, trophoblast cells that express Fas ligand (CD95L) have been demonstrated to induce apoptosis of maternal Fas (CD95)-expressing lymphocytes [49],

Table 4. Human chorionic mesenchymal stromal cells: isolation protocols, phenotype, and in vitro differentiation

Procedure	Procedure description	References	
Isolation protocols	Mechanical removal of surrounding layers after treatment with 2.4 U/ml dispase II at 37°C, followed by 1–3 hours treatment with Worthington collagenase II (270 U/ml) or collagenase A (0.83 mg/ml)	[28, 31]	
Phenotype at passages 2–4	Mesenchymal and hematopoietic markers: CD105+, CD90+, CD73+, CD44+, CD29+, HLA-A,B,C+, CD13+, CD166+, CD49e+, CD271 ^{low} , CD10+, CD14–, CD34–, CD45–, CD117–, CD133–, HLA-DR– Embryonic stem cell marker: SSEA-4–/+ Others: CD349+, CD140b+, CD324–	[28, 31, 134] (Bühring HJ, Trembl S, Cerabona F et al., unpublished data)	
Differentiation potential	Adipogenic	DMEM high glucose, 10% FBS, 0.5 mM isobutylmethylxanthine, 1 μM dexamethasone, 10 μM insulin, 200 μM indomethacin	[28]
	Chondrogenic	Bullet Kit Adipogenic Differentiation Media (Cambrex)	[31]
		DMEM high glucose, 1% FBS, 6.25 μg/ml insulin, 10 ng/ml TGF-β1, 50 ng/ml fresh ascorbic acid	[28]
		DMEM, 100 nM dexamethasone, 50 μg/ml L-ascorbic acid 2-phosphate, 1 mM sodium pyruvate, 40 μg/ml proline, ITS (5 μg/ml insulin, 5 μg/ml transferrin, 5 ng/ml selenous acid), 5 ng/ml TGF-β1	[31]
	Osteogenic	10 μM dexamethasone, 10 nM 1α, 25-dihydroxyvitamin D3, 50 μg/ml ascorbic acid, 10 mM β-glycerophosphate	[28]
	Skeletal myogenic	Bullet Kit Osteogenic Differentiation Media (Cambrex)	[31]
	Neurogenic	DMEM high glucose, 10% FBS, 5% horse serum, 50 μM hydrocortisone, 0.1 μM dexamethasone	[28, 31]
	DMEM high glucose, 10% FBS, 30 μM all-trans retinoic acid	[28]	

Abbreviations: DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; TGF, transforming growth factor.

therefore representing another possible mechanism for contributing to the maintenance of fetomaternal tolerance. The mechanisms discussed above are not definitive, and it is very likely that they all play a role in the complex phenomenon of fetal maternal tolerance.

ROLE OF FETAL MEMBRANES IN TOLERANCE

It has been proposed that cells from fetal membranes have immunoregulatory properties. Amniotic membrane and hAEC are used on skin wounds, burn injuries, and chronic leg ulcers and to prevent adhesions in surgical procedures [50–57]. Amniotic membrane is also used in ocular surface reconstruction to promote development of normal corneal or conjunctival epithelium [57] without immunosuppression or acute rejection. Furthermore, transplantation of allogenic amniotic membrane or hAEC without immunosuppression does not induce acute immune rejection [8, 58–61]. In vitro studies show that cells isolated from amniotic and chorionic membranes do not elicit an allogeneic or xenogeneic immune response but actively suppress lymphocyte proliferation [29, 41, 62]. Human amniotic membrane and hAEC have been shown to survive for prolonged times in immunocompetent animals, including rabbits [63], rats [64], guinea pigs [65], and bonnet monkeys [66]. In addition, long-term engraftment was observed after i.v. injection of heterogeneous human amniochorionic cells into newborn swine and rats, with human microchimerism detected in bone marrow, brain, lung, and thymus [41], suggesting active migration and integration into specific organs and indicating active tolerance of the xenogeneic cells.

PLACENTA AS A POTENT NICHE SOURCE FOR HEMATOPOIETIC STEM/PROGENITOR CELLS: INSIGHTS FROM THE MOUSE PLACENTA

In mouse placenta the allantois, an extension of the primitive streak, fuses with the chorionic plate, giving rise to umbilical vasculatures and mesoderm of fetal placenta. Allantoic mesoderm interdigitates with trophoblasts to form the placenta labyrinth. Allantois-derived umbilical arteries are the site of hematopoietic stem cell (HSC) ontogeny. In 1961, Till and McCulloch reported that placenta harbors transplantable hematopoietic activity [67]. Melchers detected B cell progenitors in placenta prior to their appearance in fetal liver [68]. Multipotential myeloerythroid progenitors are present at a higher frequency in mouse placenta than in yolk sac or fetal liver [69]. Mouse placenta is a niche for developing HSCs without facilitating myeloid or erythroid differentiation. The distribution of HSC in placenta and the aorta-gonad-mesonephros region was compared, a dramatic expansion of placenta HSC (50 HSC-long-term repopulating units per organ) was reported at embryonic day (E) 12.5 [70], and HSC were detected in the vascular labyrinth of placenta of Ly-6A (Sca-1) green fluorescent protein transgenic mice [71]. Hematopoietic cytokines produced by human placental MSC, such as stem cell factor, Flt 3 ligand, interleukin-6, and macrophage colony-stimulating factor, functionally support a sevenfold expansion of long-term culture-initiating cells [72], and additional factors were identified and cloned [73].

Mouse placenta serves as a source and a functional niche for HSC [74]. Prefusion allantois and chorion are potent sources for hematopoietic progenitors. Allantois and chorion, isolated prior to the union between the three major circulatory systems (um-

bilical cord, yolk sac, and cardiovascular) in the conceptus, express Runx1, a key transcriptional factor critical for HSC ontogeny, and CD41, a hallmark for initiation of definitive hematopoiesis [75], and also generate myeloid and definitive erythroid lineages following explant culture [76]. Furthermore, hemogenic potential and Runx1 expression are independent of the union of the tissues, reflecting their intrinsic hematopoietic property. The identification of critical niche components for HSCs from placenta may be useful for ex vivo HSC expansion.

PRECLINICAL STUDIES IN ANIMAL MODELS

Hepatic Regeneration

Hepatocyte transplantation has become a novel method for treatment of liver disease [77]. However, the technique is currently limited by a shortage of suitable hepatocytes for transplant procedures. The large number of hepatic genes and functions identified in human amniotic epithelium (hAE) suggest that if effective and efficient methods were developed to induce complete hepatic differentiation, hAE could be a useful source of cells for transplant procedures. Preclinical investigations with hepatic differentiation of hAEC have been promising. In vitro, differentiation procedures have yielded cells that express a number of liver functions, including the transcription factors HNF3 γ , and C/EBP α , HNF1, HNF4 α , pregnane x receptor, and constitutive androstane receptor, and differentiated liver genes, including albumin, α 1-antitrypsin (A1AT), glucose-6-phosphatase, carbamoyl phosphate synthase I (CPS-I), glutamine synthase, phosphoenolpyruvate carboxykinase, tyrosine aminotransferase, transthyretin, and the drug metabolizing genes CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2D6 2E1, 3A4, 7, and 7A1 [11, 14, 22, 23]. In addition to quantification of RNA, drug metabolism dependent on CYP1A and CYP3A enzymatic activity has been demonstrated [11, 78]. In unpublished work, the list of hepatic genes identified in hAE include transport proteins, including P-glycoprotein, multidrug resistance protein 1, ABCG2, the bile salt export pump, uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1), and ornithine transcarbamylase (OTC) (Miki T, Marongiu F, Strom S, unpublished data). Following transplantation into the liver, successful engraftment and survival of human [21, 78] or rat amniotic epithelial cells (AEC) [79] has been demonstrated. Recent unpublished work extends these observations to more than 6 months. Human A1AT could be detected by Western blot in mouse serum [14], clearly indicating that hAEC perform this important hepatic function in vivo. Human albumin was detected in the sera and peritoneal fluid of SCID mice who received peritoneal implants of human amniotic membrane [22]. At this time, there are no reports of the characterization of hepatic gene expression in long-term recipients of AE transplants or that the transplantation of AEC can support animals with acute or long-term defects in liver function. These important preclinical studies will be needed before the therapeutic potential of hAE can be fully assessed.

At least 30 genes known to be expressed in mature human liver are expressed in hAEC directed toward hepatic differentiation in culture, suggesting that transplantation of hAE-derived hepatocytes could be an effective therapy for liver disease. It is significant that among the hepatic genes expressed are A1AT, OTC, CPS-I, and UGT1A1. Mutations in these genes cause metabolic liver diseases that are currently corrected by liver transplantation. Perhaps hAEC transplants could provide a novel cell therapy for patients suffering liver or lung disease from A1AT deficiency, or those at risk for neurological effects due to

the inability to metabolize and excrete ammonia (OTC and CPS-I) or bilirubin (UGT1A1).

Cardiac Repair

Myocardial infarction, ischemia, and stroke are important consequences of end-stage occlusive vascular disease. Present-day therapies are inadequate and palliative, so stem cell therapy has been investigated. Coculture experiments with neonatal rat heart explants have confirmed that hAMSC integrate into cardiac tissues and differentiate into cardiomyocyte-like cells. After transplantation into myocardial infarcts in rat hearts, hAMSC survived for 2 months and differentiated into cardiomyocyte-like cells [37].

A mixed ester of hyaluronan and butyric and retinoic acids (HBR) was reported to promote cardiogenic/vasculogenic differentiation of human amniochorionic (AC)-derived cells. HBR enhanced the expression of cardiomyogenic genes (GATA4, NKX 2.5) and proteins (sarcomeric myosin heavy chain and α -sarcomeric actinin) but not skeletal muscle myosin D (MyoD) or neurogenic features (Neurogenin). Cells treated with HBR express both cardiac and endothelial markers, such as von Willebrand factor (vWF), and enhance cardiac repair in infarcted rat heart. AC transplants increase capillary density at the infarct border, normalize left ventricular function, and decrease scar formation. Transplantation of HBR-preconditioned AC-derived cells further enhanced capillary density and the yield of human vWF-expressing cells, also decreasing the infarct size. Some engrafted, HBR-pretreated AC-derived cells were also positive for connexin 43 and cardiac troponin I. These improvements may be related to the local or paracrine secretion of angiogenic, antiapoptotic, and mitogenic factors following human MSC transplantation, in addition to the differentiation of AC to vascular cells. These "trophic" effects may provide a major contribution to the therapeutic potential of MSCs for myocardial infarction and dilated cardiomyopathy. These findings provide an innovative approach to cell therapy of heart failure, whereby AC secrete trophic factors and, under the influence of HBR, may show enhanced cardiac and vascular differentiation [35, 80].

Placenta Derived Stem Cells for Treating Neurological Disorders

Human AEC have shown particular potential for treating central nervous system disorders. Since the discovery that hAEC have stem cell properties [11], express neural and glial markers and neural-specific proteins, and also have the capacity to produce and secrete neurotransmitters [9, 17], cell therapy with these cells has been considered [9, 16]. Successful transplants of hAEC into caudate nucleus [19, 20, 81], hippocampus [82], and spinal cord [66] have been reported. Transplantation of hAEC in a rat model of Parkinson's disease reversed the condition and prevented neuronal death [19, 20]. When hAEC were transplanted into ischemic hippocampus, they differentiated into "neuron-like" cells [82]. Following transplantation into the transected spinal cord of monkeys, hAEC aided a robust regeneration of host axons and prevented death of axotomized neurons of the spinal cord [66]. Transplantation of hAEC into the lesioned areas of a contusion model of spinal cord injury in rats was performed without immunosuppression. Cells survived up to 120 days with no evidence of inflammation or rejection. Animals showed gradual functional improvement using the Basso, Beattie, and Bresnahan (BBB) locomotor rating scale and ultimately reached a score of 19, just 2 points below normal animals. Improvement was also observed in lesion control animals; however, improvement was faster during acute and sub-acute phases of recovery in transplant recipients. Wu et al.

reported similar findings [83]. Early improvement in the BBB scale is thought to indicate that hAEC provide neuroprotection [84]. In narrow-beam and inclined-plane tests, the performance of hAEC-transplanted animals was significantly improved compared with lesion control animals. These tests measure corticospinal tract [85] and rubrospinal tract [86, 87] function, respectively. Improvement following hAEC transplants indicates improvement of pyramidal (corticospinal) and extrapyramidal (brain stem) systems of motor tracts controlling locomotion. hAEC secrete neurotrophic factors [88], whereas medium conditioned by hAEC has been shown to be neurotrophic for E18 rat cortical cells. Novel EGF-like neurotrophic factors were thought to mediate this effect [89]. hAEC-conditioned medium also supported survival of E10 chicken neural retinal cells, which were otherwise dependent on fibroblast growth factor-2 (FGF-2) [90, 91]. Although FGF-2 and EGF were not detected in media by immunoblotting, FGF-2 and EGF gene and protein expression was reported in cryopreserved hAEC [89, 92]. Recently, MSCs were found to produce "neuron-like" cells, but their function is yet to be proven [93].

In conclusion, hAEC transplants produce beneficial results in animal models of spinal cord injury. They were found to exhibit neuroprotection in acute phases of injury and facilitate regeneration of long tracts in long-term phases of recovery, as measured by behavioral assessment. The beneficial effects may be mediated through the secretion of novel neurotrophic factors.

Cell Tracking

In preclinical studies, tracking of transplanted cells is essential. Using cell labeling together with imaging, cells can be traced noninvasively [94–102]. Stem cells from different sources have been labeled using radionuclides, magnetic nanoparticles, or reporter genes, in both preclinical and clinical studies [95, 103, 104]. In contrast to other imaging techniques, luminescence imaging detects live cells, since the reporter gene, luciferase, generates photon emission only in the presence of ATP, luciferin, and oxygen [105]. Reporter gene transfection protocols established for adipose-derived stem cells have been successfully applied in hAMSC [102], allowing luminescence imaging of their survival, migration, and distribution in preclinical *in vivo* models.

CELL AND TISSUE BANKING

General Aspects of Banking for Human Use

Cell or tissue banking follows specific rules. European Community directive 2003/94/EC lays down the principles and guidelines of good manufacturing practice (GMP) for medicinal products for human use. This directive is particularized in the so-called GMP Guidelines [106]. Standards of quality and safety for the donation, procurement, testing, processing, preservation, storage, and distribution of human tissues and cells, with annotations to traceability, adverse reactions, and technical requirements concerning production and quality control, are found in directive 2004/23/EC and specified in 2006/17/EC and 2006/86/EC. Other institutions such as The European Association of Tissue Banks (ETAB) and Joint Accreditation Committee-ISCIT & EBMT (JACIE) also publish standards for cell and tissue banking and interpreting laws [107–109].

Cell Banking

So far, most experience in preservation of placental tissue-derived cells has been gained with cord blood, which contains both hematopoietic and mesenchymal stem cells. When cord

blood transplantation proved effective, many cord blood banks were established, offering collection and banking for public (allogeneic) or private (autologous or allogeneic) use. Cord blood is procured from natural births or caesarean sections [110]. Different methods for the reduction of red blood cells, plasma volume, and cryopreservation exist [111]. Cord blood products containing cryoprotectants (e.g., dimethyl sulfoxide [DMSO]) are frozen at a controlled-rate and can be stored in liquid nitrogen for at least 15 years without the loss of their engraftment potential *in vivo* [110, 112].

In contrast to cord blood [113, 114], fetal membrane stem cells are presently preserved mainly for research. However, as these cells gain interest for their regenerative and immunomodulatory properties (described above, in Immunology of the Placenta) [29, 115], future medical needs may require concomitant application of cord blood and placental cells from the same donor. After cryopreservation, hAMSC and hCMSC can be differentiated at least along the osteogenic lineage (S. Hennerbichler, unpublished data). However, no conclusive studies are so far available on the influence of cryopreservation on plasticity.

Tissue Banking

The use of amniotic membrane has history spanning almost 100 years. The first reported clinical use of amniotic membrane was in 1910, when it was applied in skin transplantation [116]. Shortly after, application was expanded to treat burned and ulcerated skin [117, 118] and conjunctival defects [119]. Since its rediscovery in 1995 [120], it has been widely applied in ophthalmology, surgery, and wound healing [121]. Besides its nearly unlimited availability, easy procurement, and low processing costs for therapeutic application, many beneficial properties of this tissue, including bacteriostatic, anti-inflammatory, analgesic, wound healing, reepithelialization, reduced scarring, and anatomical and vapor barrier properties, have been reported [56, 122–124].

Currently, freeze-dried, γ -sterilized, decellularized, glycerol-preserved, and cryopreserved amniotic membranes are used in ophthalmology and wound care [123, 125–128]. Questions remain as to how these different processing and preservation methods influence sterility, viability, and growth factor release [129, 130] (S. Hennerbichler, unpublished data).

When placentae from caesarean sections were collected, 0 of 10 tested were contaminated with aerobic or anaerobic bacteria, whereas bacteria were detected in 4 of 10 naturally born placenta tested (S. Hennerbichler, unpublished data). It may therefore be preferential to collect placentae from caesarean sections.

Membranes were further investigated for viability and growth factor release after glycerol (50% glycerol) or cryopreservation (10% DMSO). Cryopreserved membrane retained cell viability and released several angiogenic growth factors and cytokines [129, 130], whereas storage in glycerol at 4°C resulted in immediate cell death [129]. Others have confirmed that different processing methods such as irradiation influence the growth factor content of amniotic membrane [131].

CONCLUSION

In 2004, the journal *Transplantation* ran an editorial entitled "Amnion and chorion cells as therapeutic agents for transplantation and tissue regeneration: a field in its infancy" [132]. This editorial referred to one of the first reports showing that human fetal membranes harbor cells with progenitor/stem cell potential that were tolerated by the recipients such that they would engraft in animals even after xenotransplantation [40]. In this review,

we have presented recent advances in this field, with the aim of defining the placenta derived cell subpopulations and their plasticity, as well as providing protocols for their isolation and differentiation. Finally, the preclinical studies reported strongly support the hypothesis that placenta holds much promise for the development of cell-based therapies for clinical applications in the near future.

ACKNOWLEDGMENTS

We are very grateful to Prof. Gianandrea Pasquinelli and Prof. Leonardo Resta for help in revising the sections on placenta structure and embryology. We are indebted to Fondazione Car-

iplo for providing continuous and generous financial support for research into placenta derived stem cells at Centro di Ricerca E. Menni, Brescia, Italy. We sincerely thank Banca Lombarda e Piemontese for sustaining all of the costs of the international Workshop on Placenta Derived Stem Cells, held in Brescia, Italy, March 23–24, 2007.

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

S.C.S., University of Pittsburgh, has acted as a consultant and received financial compensation within the last 2 years from Cambrex, Walkersville, MD.

REFERENCES

- Zipori D. The stem state: Plasticity is essential, whereas self-renewal and hierarchy are optional. *STEM CELLS* 2005;23:719–726.
- Delorme B, Chateauvieux S, Charbord P. The concept of mesenchymal stem cells. *Regen Med* 2006;1:497–509.
- Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 2006;8:315–317.
- Magatti M, De Munari S, Vertua E et al. Human amnion mesenchyme harbors cells with allogeneic T cell suppression and stimulation capabilities. *STEM CELLS* 2007 [Epub ahead of print].
- Cunningham FG, MacDonald PC, Gant MF et al. The placenta and fetal membranes. In: Williams Obstetrics. 20th ed. Stamford, CT: Appleton and Lange, 1997:95–125.
- Benirschke K, Kaufmann P. Pathology of the human placenta. New York: Springer-Verlag, 2000:42–46, 116, 281–297.
- Moore KL, Persaud TVN. The developing human. 6th ed. Philadelphia: W.B. Saunders Company, 1998:41–62.
- Akle CA, Adinolfi M, Welsh KI et al. Immunogenicity of human amniotic epithelial cells after transplantation into volunteers. *Lancet* 1981;2:1003–1005.
- Sakuragawa N, Misawa H, Ohsugi K et al. Evidence for active acetylcholine metabolism in human amniotic epithelial cells: Applicable to intracerebral allografting for neurologic disease. *Neurosci Lett* 1997; 232:53–56.
- Terada S, Matsuura K, Enosawa S et al. Inducing proliferation of human amniotic epithelial (HAE) cells for cell therapy. *Cell Transplant* 2000; 9:701–704.
- Miki T, Lehmann T, Cai H et al. Stem cell characteristics of amniotic epithelial cells. *STEM CELLS* 2005;23:1549–1559.
- Miki T, Marongiu F, Ellis E et al. Isolation of amniotic epithelial stem cells. *Curr Protoc Stem Cell Biol* 2007 (in press).
- Ochsenbein-Kolble N, Bilic G, Hall H et al. Inducing proliferation of human amnion epithelial and mesenchymal cells for prospective engineering of membrane repair. *J Perinat Med* 2003;31:287–294.
- Miki T, Strom SC. Amnion-derived pluripotent/multipotent stem cells. *Stem Cell Rev* 2006;2:133–142.
- Tamagawa T, Ishiwata I, Saito S. Establishment and characterization of a pluripotent stem cell line derived from human amniotic membranes and initiation of germ layers in vitro. *Hum Cell* 2004;17:125–130.
- Sakuragawa N, Thangavel R, Mizuguchi M et al. Expression of markers for both neuronal and glial cells in human amniotic epithelial cells. *Neurosci Lett* 1996;209:9–12.
- Elwan MA, Sakuragawa N. Evidence for synthesis and release of catecholamines by human amniotic epithelial cells. *Neuroreport* 1997; 8:3435–3438.
- Elwan MA, Thangavel R, Ono F et al. Synthesis and release of catecholamines by cultured monkey amniotic epithelial cells. *J Neurosci Res* 1998;53:107–113.
- Kakishita K, Elwan MA, Nakao N et al. Human amniotic epithelial cells produce dopamine and survive after implantation into the striatum of a rat model of Parkinson's disease: A potential source of donor for transplantation therapy. *Exp Neurol* 2000;165:27–34.
- Kakishita K, Nakao N, Sakuragawa N et al. Implantation of human amniotic epithelial cells prevents the degeneration of nigral dopamine neurons in rats with 6-hydroxydopamine lesions. *Brain Res* 2003;980: 48–56.
- Sakuragawa N, Enosawa S, Ishii T et al. Human amniotic epithelial cells are promising transgene carriers for allogeneic cell transplantation into liver. *J Hum Genet* 2000;45:171–176.
- Takashima S, Ise H, Zhao P et al. Human amniotic epithelial cells possess hepatocyte-like characteristics and functions. *Cell Struct Funct* 2004;29:73–84.
- Davila JC, Cezar GG, Thiede M et al. Use and application of stem cells in toxicology. *Toxicol Sci* 2004;79:214–223.
- Wei JP, Zhang TS, Kawa S et al. Human amnion-isolated cells normalize blood glucose in streptozotocin-induced diabetic mice. *Cell Transplant* 2003;12:545–552.
- Bilic G, Ochsenbein-Kolble N, Hall H et al. In vitro lesion repair by human amnion epithelial and mesenchymal cells. *Am J Obstet Gynecol* 2004;190:87–92.
- In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C et al. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. *STEM CELLS* 2004;22:1338–1345.
- Sakuragawa N, Kakinuma K, Kikuchi A et al. Human amnion mesenchyme cells express phenotypes of neuroglial progenitor cells. *J Neurosci Res* 2004;78:208–214.
- Portmann-Lanz CB, Schoeberlein A, Huber A et al. Placental mesenchymal stem cells as potential autologous graft for pre- and perinatal neuroregeneration. *Am J Obstet Gynecol* 2006;194:664–673.
- Wolbank S, Peterbauer A, Fahrner M et al. Dose-dependent immunomodulatory effect of human stem cells from amniotic membrane: A comparison with human mesenchymal stem cells from adipose tissue. *Tissue Eng* 2007;13:1173–1183.
- Zhang X, Mitsuru A, Igura K et al. Mesenchymal progenitor cells derived from chorionic villi of human placenta for cartilage tissue engineering. *Biochem Biophys Res Commun* 2006;340:944–952.
- Soncini M, Vertua E, Gibelli L et al. Isolation and characterization of mesenchymal cells from human fetal membranes. *J Tissue Eng Regen Med* 2007;1:296–305.
- Moore RM, Silver RJ, Moore JJ. Physiological apoptotic agents have different effects upon human amnion epithelial and mesenchymal cells. *Placenta* 2003;24:173–180.
- Casey ML, MacDonald PC. Interstitial collagen synthesis and processing in human amnion: A property of the mesenchymal cells. *Biol Reprod* 1996;55:1253–1260.
- Zhang X, Soda Y, Takahashi K et al. Successful immortalization of mesenchymal progenitor cells derived from human placenta and the differentiation abilities of immortalized cells. *Biochem Biophys Res Commun* 2006;351:853–859.
- Alviano F, Fossati V, Marchionni C et al. Term Amniotic membrane is a high throughput source for multipotent Mesenchymal Stem Cells with the ability to differentiate into endothelial cells in vitro. *BMC Dev Biol* 2007;7:11.
- Pasquinelli G, Tazzari P, Ricci F et al. Ultrastructural characteristics of human mesenchymal stromal (stem) cells derived from bone marrow and term placenta. *Ultrastruct Pathol* 2007;31:23–31.
- Zhao P, Ise H, Hongo M et al. Human amniotic mesenchymal cells have some characteristics of cardiomyocytes. *Transplantation* 2005; 79:528–535.
- Bilic G, Zeisberger SM, Mallik A et al. *Cell Transplant* 2007 (in press).
- Miki T, Mitamura K, Ross MA et al. Identification of stem cell marker-positive cells by immunofluorescence in term human amnion. *J Reprod Immunol* 2007;75:91–96.
- Chan J, Kennea NL, Fisk NM. Placental mesenchymal stem cells. *Am J Obstet Gynecol* 2007;196:e18; author reply e18–e19.
- Bailo M, Soncini M, Vertua E et al. Engraftment potential of human amnion and chorion cells derived from term placenta. *Transplantation* 2004;78:1439–1448.
- Mellor AL, Munn DH. Immunology at the maternal-fetal interface: Lessons for T cell tolerance and suppression. *Annu Rev Immunol* 2000;18:367–391.

- 43 Munn DH, Zhou M, Attwood JT et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. *Science* 1998;281:1191–1193.
- 44 Munn DH, Shafiqzadeh E, Attwood JT et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. *J Exp Med* 1999;189:1363–1372.
- 45 Baban B, Chandler P, McCool D et al. Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. *J Reprod Immunol* 2004;61:67–77.
- 46 Fournel S, Aguerre-Girr M, Huc X et al. Cutting edge: Soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. *J Immunol* 2000;164:6100–6104.
- 47 Bainbridge DR, Ellis SA, Sargent IL. HLA-G suppresses proliferation of CD4(+) T-lymphocytes. *J Reprod Immunol* 2000;48:17–26.
- 48 Thellin O, Coumans B, Zorzi W et al. Tolerance to the foeto-placental 'graft': Ten ways to support a child for nine months. *Curr Opin Immunol* 2000;12:731–737.
- 49 Makrigiannakis A, Zoumakis E, Kalantaridou S et al. Corticotropin-releasing hormone promotes blastocyst implantation and early maternal tolerance. *Nat Immunol* 2001;2:1018–1024.
- 50 Colocho G, Graham WP, 3rd, Greene AE et al. Human amniotic membrane as a physiologic wound dressing. *Arch Surg* 1974;109:370–373.
- 51 Gruss JS, Jirsch DW. Human amniotic membrane: A versatile wound dressing. *Can Med Assoc J* 1978;118:1237–1246.
- 52 Trelford JD, Trelford-Sauder M. The amnion in surgery, past and present. *Am J Obstet Gynecol* 1979;134:833–845.
- 53 Faulk WP, Matthews R, Stevens PJ et al. Human amnion as an adjunct in wound healing. *Lancet* 1980;1:1156–1158.
- 54 Ward DJ, Bennett JP. The long-term results of the use of human amnion in the treatment of leg ulcers. *Br J Plast Surg* 1984;37:191–193.
- 55 Ward DJ, Bennett JP, Burgos H et al. The healing of chronic venous leg ulcers with prepared human amnion. *Br J Plast Surg* 1989;42:463–467.
- 56 Subrahmanyam M. Amniotic membrane as a cover for microskin grafts. *Br J Plast Surg* 1995;48:477–478.
- 57 Gomes JA, Romano A, Santos MS et al. Amniotic membrane use in ophthalmology. *Curr Opin Ophthalmol* 2005;16:233–240.
- 58 Tytki-Szymanska A, Maciejko D, Kidawa M et al. Amniotic tissue transplantation as a trial of treatment in some lysosomal storage diseases. *J Inher Metab Dis* 1985;8:101–104.
- 59 Yeager AM, Singer HS, Buck JR et al. A therapeutic trial of amniotic epithelial cell implantation in patients with lysosomal storage diseases. *Am J Med Genet* 1985;22:347–355.
- 60 Scaggiante B, Pineschi A, Sustersich M et al. Successful therapy of Niemann-Pick disease by implantation of human amniotic membrane. *Transplantation* 1987;44:59–61.
- 61 Sakuragawa N, Yoshikawa H, Sasaki M. Amniotic tissue transplantation: Clinical and biochemical evaluations for some lysosomal storage diseases. *Brain Dev* 1992;14:7–11.
- 62 Li H, Niederkorn JY, Neelam S et al. Immunosuppressive factors secreted by human amniotic epithelial cells. *Invest Ophthalmol Vis Sci* 2005;46:900–907.
- 63 Avila M, Espana M, Moreno C et al. Reconstruction of ocular surface with heterologous limbal epithelium and amniotic membrane in a rabbit model. *Cornea* 2001;20:414–420.
- 64 Kubo M, Sonoda Y, Muramatsu R et al. Immunogenicity of human amniotic membrane in experimental xenotransplantation. *Invest Ophthalmol Vis Sci* 2001;42:1539–1546.
- 65 Yuge I, Takumi Y, Koyabu K et al. Transplanted human amniotic epithelial cells express connexin 26 and Na-K-adenosine triphosphatase in the inner ear. *Transplantation* 2004;77:1452–1454.
- 66 Sankar V, Muthusamy R. Role of human amniotic epithelial cell transplantation in spinal cord injury repair research. *Neuroscience* 2003;118:11–17.
- 67 Till JE, McCulloch E. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. *Radiat Res* 1961;14:213–222.
- 68 Melchers F. Murine embryonic B lymphocyte development in the placenta. *Nature* 1979;277:219–221.
- 69 Alvarez-Silva M, Belo-Diabanguouaya P, Salaun J et al. Mouse placenta is a major hematopoietic organ. *Development* 2003;130:5437–5444.
- 70 Gekas C, Dieterlen-Lievre F, Orkin SH et al. The placenta is a niche for hematopoietic stem cells. *Dev Cell* 2005;8:365–375.
- 71 Ottersbach K, Dzierzak E. The murine placenta contains hematopoietic stem cells within the vascular labyrinth region. *Dev Cell* 2005;8:377–387.
- 72 Zhang Y, Li C, Jiang X et al. Human placenta-derived mesenchymal progenitor cells support culture expansion of long-term culture-initiating cells from cord blood CD34+ cells. *Exp Hematol* 2004;32:657–664.
- 73 Nakajima H, Shibata F, Fukuchi Y et al. Immune suppressor factor confers stromal cell line with enhanced supporting activity for hematopoietic stem cells. *Biochem Biophys Res Commun* 2006;340:35–42.
- 74 Mikkola HK, Gekas C, Orkin SH et al. Placenta as a site for hematopoietic stem cell development. *Exp Hematol* 2005;33:1048–1054.
- 75 Corbel C, Salaun J, Belo-Diabanguouaya P et al. Hematopoietic potential of the pre-fusion allantois. *Dev Biol* 2007;301:478–488.
- 76 Zeigler BM, Sugiyama D, Chen M et al. The allantois and chorion, when isolated before circulation or chorio-allantoic fusion, have hematopoietic potential. *Development* 2006;133:4183–4192.
- 77 Strom SC, Bruzzone P, Cai H et al. Hepatocyte transplantation: Clinical experience and potential for future use. *Cell Transplant* 2006;15(suppl 1):S105–S110.
- 78 Miki T, Cai H, Lehmann T et al. Production of hepatocytes from human amniotic stem cells. *Hepatology* 2002;36(4):171A.
- 79 Nakajima T, Enosawa S, Mitani T et al. Cytological examination of rat amniotic epithelial cells and cell transplantation to the liver. *Cell Transplant* 2001;10:423–427.
- 80 Ventura C, Cantoni S, Bianchi F et al. Hyaluronan mixed esters of butyric and retinoic acid drive cardiac and endothelial fate in term placenta human mesenchymal stem cells and enhance cardiac repair in infarcted rat hearts. *J Biol Chem* 2007;282:14243–14252.
- 81 Bankiewicz KS, Palmatier M, Plunkett RJ et al. Reversal of hemiparkinsonian syndrome in nonhuman primates by amnion implantation into caudate nucleus. *J Neurosurg* 1994;81:869–876.
- 82 Okawa H, Okuda O, Arai H et al. Amniotic epithelial cells transform into neuron-like cells in the ischemic brain. *Neuroreport* 2001;12:4003–4007.
- 83 Wu ZY, Hui GZ, Lu Y et al. Transplantation of human amniotic epithelial cells improves hindlimb function in rats with spinal cord injury. *Chin Med J (Engl)* 2006;119:2101–2107.
- 84 Hasegawa K, Chang YW, Li H et al. Embryonic radial glia bridge spinal cord lesions and promote functional recovery following spinal cord injury. *Exp Neurol* 2005;193:394–410.
- 85 Merkle D, Metz GA, Raineteau O et al. Locomotor recovery in spinal cord-injured rats treated with an antibody neutralizing the myelin-associated neurite growth inhibitor Nogo-A. *J Neurosci* 2001;21:3665–3673.
- 86 Rivlin AS, Tator CH. Objective clinical assessment of motor function after experimental spinal cord injury in the rat. *J Neurosurg* 1977;47:577–581.
- 87 Fehlings MG, Tator CH. The relationships among the severity of spinal cord injury, residual neurological function, axon counts, and counts of retrogradely labeled neurons after experimental spinal cord injury. *Exp Neurol* 1995;132:220–228.
- 88 Uchida S, Inanaga Y, Kobayashi M et al. Neurotrophic function of conditioned medium from human amniotic epithelial cells. *J Neurosci Res* 2000;62:585–590.
- 89 Sakuragawa N, Elwan MA, Uchida S et al. Non-neuronal neurotransmitters and neurotrophic factors in amniotic epithelial cells: Expression and function in humans and monkey. *Jpn J Pharmacol* 2001;85:20–23.
- 90 Tchong M, Oliver L, Courtois Y et al. Effects of exogenous FGFs on growth, differentiation, and survival of chick neural retina cells. *Exp Cell Res* 1994;212:30–35.
- 91 Pittack C, Grunwald GB, Reh TA. Fibroblast growth factors are necessary for neural retina but not pigmented epithelium differentiation in chick embryos. *Development* 1997;124:805–816.
- 92 Koizumi NJ, Inatomi TJ, Sotozono CJ et al. Growth factor mRNA and protein in preserved human amniotic membrane. *Curr Eye Res* 2000;20:173–177.
- 93 Choi CB, Cho YK, Prakash KV et al. Analysis of neuron-like differentiation of human bone marrow mesenchymal stem cells. *Biochem Biophys Res Commun* 2006;350:138–146.
- 94 Gao J, Dennis JE, Muzic RF et al. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. *Cells Tissues Organs* 2001;169:12–20.
- 95 Wang X, Rosol M, Ge S et al. Dynamic tracking of human hematopoietic stem cell engraftment using in vivo bioluminescence imaging. *Blood* 2003;102:3478–3482.
- 96 Wu JC, Chen IY, Sundaresan G et al. Molecular imaging of cardiac cell transplantation in living animals using optical bioluminescence and positron emission tomography. *Circulation* 2003;108:1302–1305.
- 97 Kim DE, Schellingerhout D, Ishii K et al. Imaging of stem cell recruitment to ischemic infarcts in a murine model. *Stroke* 2004;35:952–957.
- 98 Leo BM, Li X, Balian G et al. In vivo bioluminescent imaging of virus-mediated gene transfer and transduced cell transplantation in the intervertebral disc. *Spine* 2004;29:838–844.
- 99 Niyibizi C, Wang S, Mi Z et al. The fate of mesenchymal stem cells transplanted into immunocompetent neonatal mice: Implications for skeletal gene therapy via stem cells. *Mol Ther* 2004;9:955–963.
- 100 Okada S, Ishii K, Yamane J et al. In vivo imaging of engrafted neural stem cells: Its application in evaluating the optimal timing of transplantation for spinal cord injury. *FASEB J* 2005;19:1839–1841.
- 101 Cao F, Lin S, Xie X et al. In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. *Circulation* 2006;113:1005–1014.

- 102 Wolbank S, Peterbauer A, Wassermann E et al. Labelling of human adipose-derived stem cells for non-invasive in vivo cell tracking. *Cell Tissue Bank* 2006;8:163–177.
- 103 Hofmann M, Wollert KC, Meyer GP et al. Monitoring of bone marrow cell homing into the infarcted human myocardium. *Circulation* 2005; 111:2198–2202.
- 104 Kraitchman DL, Heldman AW, Atalar E et al. In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. *Circulation* 2003;107:2290–2293.
- 105 Contag CH, Contag PR, Mullins JI et al. Photonic detection of bacterial pathogens in living hosts. *Mol Microbiol* 1995;18:593–603.
- 106 Brychta P. EATB: Standards for banking of biologic skin substitutes (BSS). *Cell Tissue Bank* 2002;3:59–71.
- 107 Cobo F, Cabrera C, Catalina P et al. General safety guidances in stem cell bank installations. *Cytotherapy* 2006;8:47–56.
- 108 Common Standards for Tissue and Cell Banking (EATB, EAMST, EEBA). Available at <http://www.eatb.de>. Accessed May 15, 2007.
- 109 EudraLex. Volume 4. Medicinal Products for Human and Veterinary Use: Good Manufacturing Practice. Available at <http://ec.europa.eu/enterprise/pharmaceuticals/homev4.htm>. Accessed May 15, 2007.
- 110 Chrysler GR, McKenna DH, T S et al. Cord Blood Banking. In: Broxmeyer HE, ed. *Cord blood: Biology, immunology, banking and clinical transplantation*. Bethesda, MD: AABB Press, 2004:219–257.
- 111 Lapierre V, Pellegrini N, Bardey I et al. Cord blood volume reduction using an automated system (Sepax) vs. a semi-automated system (Optipress II) and a manual method (hydroxyethyl starch sedimentation) for routine cord blood banking: A comparative study. *Cytotherapy* 2007;9: 165–169.
- 112 Skoric D, Balint B, Petakov M et al. Collection strategies and cryopreservation of umbilical cord blood. *Transfus Med* 2007;17:107–113.
- 113 Broxmeyer HE, Douglas GW, Hangoc G et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. *Proc Natl Acad Sci U S A* 1989;86:3828–3832.
- 114 Gluckman E, Broxmeyer HA, Auerbach AD et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. *N Engl J Med* 1989;321:1174–1178.
- 115 Parolini O, Soncini M. Human placenta: A source of progenitor/stem cells? *J Reprod Med Endocrinol* 2006;3(2):117–126.
- 116 Davis JW. Skin transplantation with a review of 550 cases at the John Hopkins Hospital. *Johns Hopkins Med J* 1910;15:307–396.
- 117 Stern W. The grafting of preserved amniotic membrane to burned and ulcerated skin. *JAMA* 1913;13:973–974.
- 118 Sabella W. Use of fetal membranes in skin grafting. *Med Rec NY* 1913;83:478–480.
- 119 de Roth A. Plastic repair of conjunctival defects with fetal membranes. *Arch Ophthalmol* 1940;23:522–525.
- 120 Kim JC, Tseng SC. Transplantation of preserved human amniotic membrane for surface reconstruction in severely damaged rabbit corneas. *Cornea* 1995;14:473–484.
- 121 Tosi GM, Massaro-Giordano M, Caporossi A et al. Amniotic membrane transplantation in ocular surface disorders. *J Cell Physiol* 2005;202:849–851.
- 122 Ganatra MA. Amniotic membrane in surgery. *J Pak Med Assoc* 2003; 53:29–32.
- 123 Dua HS, Gomes JA, King AJ et al. The amniotic membrane in ophthalmology. *Surv Ophthalmol* 2004;49:51–77.
- 124 Hao Y, Ma DH, Hwang DG et al. Identification of antiangiogenic and antiinflammatory proteins in human amniotic membrane. *Cornea* 2000; 19:348–352.
- 125 Tseng SC, Prabhasawat P, Lee SH. Amniotic membrane transplantation for conjunctival surface reconstruction. *Am J Ophthalmol* 1997;124: 765–774.
- 126 Ravishanker R, Bath AS, Roy R. “Amnion Bank”—The use of long term glycerol preserved amniotic membranes in the management of superficial and superficial partial thickness burns. *Burns* 2003;29: 369–374.
- 127 Burman S, Tejwani S, Vemuganti GK et al. Ophthalmic applications of preserved human amniotic membrane: A review of current indications. *Cell Tissue Bank* 2004;5:161–175.
- 128 Branski L, Jeschke M, Celis M et al. The treatment of partial thickness burns: Amnion versus topical antimicrobial creme. *J Surg Res* 2006; 130:276–277.
- 129 Hennerbichler S, Reichl B, Pleiner D et al. The influence of various storage conditions on cell viability in amniotic membrane. *Cell Tissue Bank* 2007;8:1–8.
- 130 Hennerbichler S, Reichl B, Wolbank S et al. Cryopreserved amniotic membrane releases angiogenic factors. *Wound Rep Reg* 2007;15: A51.
- 131 Branski L, Kulp G, Jeschke M et al. Amniotic membrane as wound coverage: The effects of irradiation and different processing methods on growth factor content. *J Surg Res* 2007;137:339.
- 132 Heeger PS. Amnion and chorion cells as therapeutic agents for transplantation and tissue regeneration: A field in its infancy. *Transplantation* 2004;78:1411–1412.
- 133 Ilancheran S, Michalska A, Peh G et al. Stem cells derived from human fetal membranes display multi-lineage differentiation potential. *Biol Reprod* 2007;77:577–588.
- 134 Battula VL, Bareiss PM, Tremel S et al. Human placenta and bone marrow derived MSC cultured in serum-free, b-FGF-containing medium express cell surface frizzled-9 and SSEA-4 and give rise to multilineage differentiation. *Differentiation* 2007;75:279–291.